Chlorhexidine to Prevent Catheter-related Urinary Tract Infection

NACompletedINTERVENTIONAL
Enrollment

30,994

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

April 30, 2024

Conditions
Urinary Tract Infections
Interventions
OTHER

Long Intervention

Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 2 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 6-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.

OTHER

Mid-length Intervention

Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 4 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 4-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.

OTHER

Short Intervention

Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 6 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 2-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

National Taiwan University Hospital, Yun-Lin Branch

OTHER

collaborator

Hualien Tzu Chi General Hospital

OTHER

collaborator

National Taiwan University Hospital Hsin-Chu Branch

OTHER

collaborator

Lotung Poh-Ai Hospital

OTHER

collaborator

Min-Sheng General Hospital

OTHER

lead

National Taiwan University Hospital

OTHER